Envista Q4 2025 slides reveal strong performance with 22% EBITDA growth, shares rise

Envista Holdings Corporation (NYSE:NVST) reported a significant surge in financial performance during its fourth-quarter and full-year 2025 earnings presentation on February 5, 2026, driven by robust demand across its dental product portfolio and strategic operational improvements. The company's earnings per share reached $0.38, comfortably beating analyst estimates of $0.32, while quarterly revenue climbed to $751 million against an expected $680.25 million. This strong showing triggered an immediate positive reaction in the equity markets, with shares rising 4.44% in post-market trading as investors responded to the double-digit core sales growth and enhanced profitability metrics. The detailed financial data revealed that Envista’s adjusted EBITDA for the fourth quarter jumped 22% year-over-year to $111 million, maintaining a healthy margin of 14.8%. This growth was fueled by both the Specialty Products & Technologies segment, which includes orthodontics and implants, and the Equipment & Consumables division. Despite some margin compression in the equipment sector due to heavy investments in new product commercialization and unfavorable currency fluctuations, the overall core sales growth of 10.8% indicated a resilient market position and successful price capture strategies. Looking ahead to 2026, CEO Paul Keel expressed optimism regarding the company's long-term trajectory, despite a more moderated outlook for the coming year. For the full year 2025, Envista achieved a 63% increase in adjusted earnings per share compared to 2024 and returned $166 million to shareholders via buybacks. The company’s 2026 guidance focuses on sustained growth and high single-digit adjusted EBITDA increases, supported by a Value Creation Plan that emphasizes operational excellence and a continued pipeline of innovative dental health technologies.